Aurion Biotechnologies is a clinical-stage biotech company focused on developing innovative therapies to restore vision, particularly for patients suffering from corneal endothelial diseases. Their lead product, Vyznova®, is a patented cell therapy designed to treat bullous keratopathy of the cornea, a condition that can lead to significant vision impairment. The therapy utilizes healthy cells harvested from donor corneas, which are then propagated through a proprietary multistep process. This method allows for the production of sufficient cultured cells to treat over 1,000 recipient eyes from a single donor, making it a scalable solution for addressing corneal blindness. The procedure is minimally invasive, with a rapid recovery time of approximately 2 to 3 hours, and has shown promising results in early clinical trials conducted in Japan.

The company has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and is progressing with clinical trials in the United States, where they anticipate topline results from their Phase 1/2 trial in early 2025. Aurion Biotech's commitment to advancing cell therapy for ocular diseases is underscored by their experienced leadership team, which includes experts in ophthalmology, clinical development, and regulatory affairs. Their innovative approach aims to provide effective and accessible treatments for millions of individuals affected by sight-threatening corneal conditions, thereby significantly improving patients' quality of life.

United States

Aurion Biotech is a clinical stage biotech company, developing a transformational platform of advanced therapies to cure blindness. Our first candidate is for the treatment of corneal endothelial disease, and one of the first clinically validated cell therapies for corneal care.

Aurion Biotechnologies

Company Details